Disc Medicine (IRON) reported a FY 2025 net loss of USD 212.2 million and a loss from operations of USD 236.0 million, with R&D expenses of USD 170.6 million and SG&A expenses of USD 65.4 million. The company ended 2025 with USD 791.2 million in cash, cash equivalents and marketable securities and said this is expected to fund operating plans into 2029. On the business side, Disc said it received an FDA Complete Response Letter in February 2026 for bitopertin in erythropoietic protoporphyria related to the sufficiency of evidence linking percent change in PPIX to sunlight exposure-based endpoints. The company is continuing the Phase 3 APOLLO trial, with enrollment expected to complete in March 2026 and topline data expected in Q4 2026; following APOLLO, Disc expects to submit a response to the CRL and receive an FDA decision by mid-2027. Disc also highlighted Phase 2 data for DISC-0974 in anemia of myelofibrosis presented at ASH and said it initiated a Phase 2 study in inflammatory bowel disease-related anemia in Q1 2026 with initial data expected in 2027. For DISC-3405, Disc said it is progressing a Phase 2 study in polycythemia vera and initiated a Phase 1b study in sickle cell disease in Q4 2025, with initial data from both expected in 2H 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Disc Medicine Inc. i published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602260830PRIMZONEFULLFEED9661473) on February 26, 2026, and is solely responsible for the information contained therein.